{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T05:45:06Z","timestamp":1768887906997,"version":"3.49.0"},"reference-count":36,"publisher":"Aboutscience Srl","issue":"Suppl. 2","license":[{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Grhta"],"abstract":"<jats:p>Introduction:\u00a0The therapeutic approach to the patient with acute bacterial skin and skin structure infection (ABSSSI) and complicated infections often involves the early transition from intravenous to oral therapy (early switch) or early discharge. Our study aimed to evaluate sustainable and innovative care models that can be transferred to community healthcare and the economic impact of dalbavancin therapy vs Standard of Care (SoC) therapy for the treatment of ABSSSI and other Gram-positive infections including those by multidrug-resistant organisms. We also described the organization of an infectious disease network that allows optimizing the treatment of ABSSSI and other complex infections with dalbavancin.\nMaterials and Methods:\u00a0We retrospectively studied all patients treated with dalbavancin in the University Hospital \u201cS. Anna\u201d of Ferrara, Italy, between November 2016 and December 2022. The clinical information of each patient was collected from the hospital\u2019s SAP database and used to evaluate the impact of dalbavancin in early discharge with reduction of length of stay promoting dehospitalization and in improving adherence to antibiotic therapy\nResults:\u00a0A total of 287 patients (165 males and 122 females) were included in the study of which 62 were treated with dalbavancin. In 13\/62 patients dalbavancin was administered in a single dose at the completion of therapy to facilitate early discharge. Assuming a 12-day hospitalization required for the treatment of ABSSSI or to complete the treatment of osteomyelitis or spondilodiscitis, the treatment with dalbavancin results in a cost reduction of more than \u20ac3,200 per single patient compared to SoC (dancomycin, linezolid or vancomycin)\nConclusions:\u00a0Dalbavancin has proven to be a valid therapeutic aid in the organization of a territorial infectious disease network given its prolonged action, which allows the dehospitalization with management of even patients with complex infections in outpatient parenteral antimicrobial therapy.<\/jats:p>","DOI":"10.33393\/grhta.2024.3094","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T11:07:04Z","timestamp":1722251224000},"page":"5-12","source":"Crossref","is-referenced-by-count":2,"title":["Clinical, organizational, and pharmacoeconomic perspectives of dalbavancin vs standard of care in the infectious disease network"],"prefix":"10.33393","volume":"11","author":[{"given":"Daniela","family":"Segala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariachiara","family":"Di Nuzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Benazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurora","family":"Bonazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Gentili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian","family":"Scolz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Marra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"Cultrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18642","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"key":"12564","doi-asserted-by":"crossref","unstructured":"Giuliano G, Raffaelli F, Faliero D, et al. Outpatient parenteral antimicrobial therapy (OPAT) from an emergency model applied during the COVID-19 pandemic to standard of care: preliminary lessons from our experience. Infect Dis Now. 2023;53(2):104642. https:\/\/doi.org\/10.1016\/j.idnow.2023.01.002 PMID:36642101","DOI":"10.1016\/j.idnow.2023.01.002"},{"key":"12565","doi-asserted-by":"crossref","unstructured":"Mansour O, Keller S, Katz M, Townsend JL. Outpatient parenteral antimicrobial therapy in the time of COVID-19: the urgent need for better insurance coverage. Open Forum Infect Dis. 2020;7(8):ofaa287. https:\/\/doi.org\/10.1093\/ofid\/ofaa287 PMID:32832575","DOI":"10.1093\/ofid\/ofaa287"},{"key":"12566","unstructured":"Kwok CS, Whittaker JJ, Malbon C, et al. Outpatient parenteral antimicrobial therapy (OPAT) service is associated with inpatient-bed cost savings. Br J Cardiol. 2021;28(3):38. PMID:35747699"},{"key":"12567","doi-asserted-by":"crossref","unstructured":"Sumi CD, Heffernan AJ, Lipman J, Roberts JA, Sime FB. What antibiotic exposures are required to suppress the emergence of resistance for Gram-negative bacteria? A systematic review. Clin Pharmacokinet. 2019;58(11):1407-1443. https:\/\/doi.org\/10.1007\/s40262-019-00791-z PMID:31325141","DOI":"10.1007\/s40262-019-00791-z"},{"key":"12568","doi-asserted-by":"crossref","unstructured":"Clarkson AM, Snape S. Clinical effectiveness of continuous infusion flucloxacillin in the outpatient parenteral antimicrobial therapy (OPAT) setting in a UK hospital: a service evaluation. Antibiotics (Basel). 2024;13(2):153. https:\/\/doi.org\/10.3390\/antibiotics13020153 PMID:38391538","DOI":"10.3390\/antibiotics13020153"},{"key":"12569","doi-asserted-by":"crossref","unstructured":"Gatti M, Andreoni M, Pea F, Viale P. Real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: a careful appraisal beyond approved indications focusing on unmet clinical needs. Drug Des Devel Ther. 2021;15:3349-3378. https:\/\/doi.org\/10.2147\/DDDT.S313756 PMID:34376971","DOI":"10.2147\/DDDT.S313756"},{"key":"12570","doi-asserted-by":"crossref","unstructured":"Ioannou P, Wolff N, Mathioudaki A, Spanias C, Spernovasilis N, Kofteridis DP. Real-world data regarding dalbavancin use before and during the COVID-19 pandemic \u2013 a single-center retrospective study. Antibiotics (Basel). 2023;12(7):1205. https:\/\/doi.org\/10.3390\/antibiotics12071205 PMID:37508301","DOI":"10.3390\/antibiotics12071205"},{"key":"12571","doi-asserted-by":"crossref","unstructured":"Lueking R, Wei W, Mang NS, Ortwine JK, Meisner J. Evaluation of dalbavancin use on clinical outcomes, cost-savings, and adherence at a large safety net hospital. Microbiol Spectr. 2023;11(1):e0238522. https:\/\/doi.org\/10.1128\/spectrum.02385-22 PMID:36537818","DOI":"10.1128\/spectrum.02385-22"},{"key":"12572","doi-asserted-by":"crossref","unstructured":"Dalovisio JR, Juneau J, Baumgarten K, Kateiva J. Financial impact of a home intravenous antibiotic program on a Medicare managed care program. Clin Infect Dis. 2000;30(4):639-642. https:\/\/doi.org\/10.1086\/313755 PMID:10770722","DOI":"10.1086\/313755"},{"key":"12573","doi-asserted-by":"crossref","unstructured":"Nazli Zeka A, Avkan-Oguz V, Irmak C, et al. Daily inpatient ertapenem therapy can be an alternative to hospitalization for the treatment of complicated urinary tract infections during the COVID-19 pandemic. Int J Clin Pract. 2021;75(7):e14230. https:\/\/doi.org\/10.1111\/ijcp.14230 PMID:33864405","DOI":"10.1111\/ijcp.14230"},{"key":"12574","doi-asserted-by":"crossref","unstructured":"Rentala M, Andrews S, Tiberio A, et al. Intravenous home infusion therapy instituted from a 24-hour clinical decision unit for patients with cellulitis. Am J Emerg Med. 2016;34(7):1273-1275. https:\/\/doi.org\/10.1016\/j.ajem.2016.04.022 PMID:27182030","DOI":"10.1016\/j.ajem.2016.04.022"},{"key":"12575","doi-asserted-by":"crossref","unstructured":"Kayley J, Berendt AR, Snelling MJ, et al. Safe intravenous antibiotic therapy at home: experience of a UK based programme. J Antimicrob Chemother. 1996;37(5):1023-1029. https:\/\/doi.org\/10.1093\/jac\/37.5.1023 PMID:8737154","DOI":"10.1093\/jac\/37.5.1023"},{"key":"12576","doi-asserted-by":"crossref","unstructured":"Martone WJ, Lindfield KC, Katz DE. Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry. Int J Clin Pract. 2008;62(8):1183-1187. https:\/\/doi.org\/10.1111\/j.1742-1241.2008.01824.x PMID:18705821","DOI":"10.1111\/j.1742-1241.2008.01824.x"},{"key":"12577","doi-asserted-by":"crossref","unstructured":"Wolter JM, Cagney RA, McCormack JG. A randomized trial of home vs hospital intravenous antibiotic therapy in adults with infectious diseases. J Infect. 2004;48(3):263-268. https:\/\/doi.org\/10.1016\/S0163-4453(03)00135-X PMID:15001305","DOI":"10.1016\/S0163-4453(03)00135-X"},{"key":"12578","doi-asserted-by":"crossref","unstructured":"Board N, Brennan N, Caplan GA. A randomised controlled trial of the costs of hospital as compared with hospital in the home for acute medical patients. Aust N Z J Public Health. 2000;24(3):305-311. https:\/\/doi.org\/10.1111\/j.1467-842X.2000.tb01573.x PMID:10937409","DOI":"10.1111\/j.1467-842X.2000.tb01573.x"},{"key":"12579","doi-asserted-by":"crossref","unstructured":"Corwin P, Toop L, McGeoch G, et al. Randomised controlled trial of intravenous antibiotic treatment for cellulitis at home compared with hospital. BMJ. 2005;330(7483):129. PMID:15604157","DOI":"10.1136\/bmj.38309.447975.EB"},{"key":"12580","doi-asserted-by":"crossref","unstructured":"Marcellusi A, Bini C, Rotundo MA, Cultrera R, Mennini FS. Costo-utilit\u00e0 di dalbavancina vs standard of care (SoC) in ABSSSI non severa in ItaliaGlob Reg. Health Technol Assess. 2020;7(1):92-100.","DOI":"10.33393\/grhta.2020.2138"},{"key":"12581","doi-asserted-by":"crossref","unstructured":"Marcellusi A, Bini C, Andreoni M, et al. Budget impact analysis of dalbavancin in the treatment of acute bacterial skin and skin structure infections in three European countries. Clin Drug Investig. 2020;40(4):305-318. https:\/\/doi.org\/10.1007\/s40261-020-00891-w PMID:32034687","DOI":"10.1007\/s40261-020-00891-w"},{"key":"12582","doi-asserted-by":"crossref","unstructured":"Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169-2179. https:\/\/doi.org\/10.1056\/NEJMoa1310480 PMID:24897082","DOI":"10.1056\/NEJMoa1310480"},{"key":"12583","doi-asserted-by":"crossref","unstructured":"Tobudic S, Forstner C, Burgmann H, et al. Dalbavancin as primary and sequential treatment for Gram-positive infective endocarditis: 2-year experience at the General Hospital of Vienna. Clin Infect Dis. 2018;67(5):795-798. https:\/\/doi.org\/10.1093\/cid\/ciy279 PMID:29659732","DOI":"10.1093\/cid\/ciy279"},{"key":"12584","doi-asserted-by":"crossref","unstructured":"Guleri A, More R, Sharma R, Wong M, Abdelrahman A. Use of dalbavancin in infective endocarditis: a case series. JAC Antimicrob Resist. 2021;3(3):dlab099. https:\/\/doi.org\/10.1093\/jacamr\/dlab099 PMID:34396119","DOI":"10.1093\/jacamr\/dlab099"},{"key":"12585","doi-asserted-by":"crossref","unstructured":"Seaton RA, Johal S, Coia JE, Reid N, Cooper S, Jones BL. Economic evaluation of treatment for MRSA complicated skin and soft tissue infections in Glasgow hospitals. Eur J Clin Microbiol Infect Dis. 2014;33(3):305-311. https:\/\/doi.org\/10.1007\/s10096-013-1956-z PMID:23995977","DOI":"10.1007\/s10096-013-1956-z"},{"key":"12586","doi-asserted-by":"crossref","unstructured":"Itani KM, Merchant S, Lin SJ, Akhras K, Alandete JC, Hatoum HT. Outcomes and management costs in patients hospitalized for skin and skin-structure infections. Am J Infect Control. 2011;39(1):42-49. https:\/\/doi.org\/10.1016\/j.ajic.2010.03.018 PMID:20673598","DOI":"10.1016\/j.ajic.2010.03.018"},{"key":"12587","doi-asserted-by":"crossref","unstructured":"Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? Int J Infect Dis. 2005;9(3):127-138. https:\/\/doi.org\/10.1016\/j.ijid.2004.09.009 PMID:15840453","DOI":"10.1016\/j.ijid.2004.09.009"},{"key":"12588","doi-asserted-by":"crossref","unstructured":"Nowak MA, Winner JS, Beilke MA. Prolonged oral antibiotic suppression in osteomyelitis and associated outcomes in a Veterans population. Am J Health Syst Pharm. 2015;72(23)(suppl 3):S150-S155. https:\/\/doi.org\/10.2146\/sp150022 PMID:26582301","DOI":"10.2146\/sp150022"},{"key":"12589","unstructured":"Fantoni M, Taccari F, Giovannenze F. Systemic antibiotic treatment of chronic osteomyelitis in adults. Eur Rev Med Pharmacol Sci. 2019;23(2)(suppl):258-270. PMID:30977893"},{"key":"12590","doi-asserted-by":"crossref","unstructured":"Sendi P, Lora-Tamayo J, Cortes-Penfield NW, U\u00e7kay I. Early switch from intravenous to oral antibiotic treatment in bone and joint infections. Clin Microbiol Infect. 2023;29(9):1133-1138. https:\/\/doi.org\/10.1016\/j.cmi.2023.05.008 PMID:37182643","DOI":"10.1016\/j.cmi.2023.05.008"},{"key":"12591","doi-asserted-by":"crossref","unstructured":"Cojutti PG, Gatti M, Punt N, et al. Implementation and validation of a Bayesian method for accurately forecasting duration of optimal pharmacodynamic target attainment with dalbavancin during long-term use for subacute and chronic staphylococcal infections. Int J Antimicrob Agents. 2024;63(1):107038. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.107038 PMID:37981075","DOI":"10.1016\/j.ijantimicag.2023.107038"},{"key":"12592","doi-asserted-by":"crossref","unstructured":"Streifel AC, Sikka MK, Bowen CD, Lewis JS II. Dalbavancin use in an academic medical centre and associated cost savings. Int J Antimicrob Agents. 2019;54(5):652-654. https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.08.007 PMID:31398481","DOI":"10.1016\/j.ijantimicag.2019.08.007"},{"key":"12593","doi-asserted-by":"crossref","unstructured":"Bookstaver PB, Milgrom A. Stewarding the costly antibiotic: considerations for dalbavancin. Clin Infect Dis. 2021;73(7):e1443-e1444. https:\/\/doi.org\/10.1093\/cid\/ciaa1730 PMID:33211844","DOI":"10.1093\/cid\/ciaa1730"},{"key":"12594","doi-asserted-by":"crossref","unstructured":"Poliseno M, Bavaro DF, Brindicci G, et al. Dalbavancin efficacy and impact on hospital length-of-stay and treatment costs in different Gram-positive bacterial infections. Clin Drug Investig. 2021;41(5):437-448. https:\/\/doi.org\/10.1007\/s40261-021-01028-3 PMID:33884583","DOI":"10.1007\/s40261-021-01028-3"},{"key":"12595","unstructured":"Wilke M, Worf K, Preisend\u00f6rfer B, Heinlein W, Kast T, Bodmann K-F. Potential savings through single-dose intravenous Dalbavancin in long-term MRSA infection treatment \u2013 a health economic analysis using German DRG data. GMS Infect Dis. 2019;7:Doc03. PMID:31728264"},{"key":"12596","doi-asserted-by":"crossref","unstructured":"Morrisette T, Miller MA, Montague BT, Barber GR, McQueen RB, Krsak M. Long-acting lipoglycopeptides: \u201clineless antibiotics\u201d for serious infections in persons who use drugs. Open Forum Infect Dis. 2019;6(7):ofz274. https:\/\/doi.org\/10.1093\/ofid\/ofz274 PMID:31281868","DOI":"10.1093\/ofid\/ofz274"},{"key":"12597","doi-asserted-by":"crossref","unstructured":"Agarwal R, Bartsch SM, Kelly BJ, et al. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis. Clin Microbiol Infect. 2018;24(4):361-368. https:\/\/doi.org\/10.1016\/j.cmi.2017.08.028 PMID:28882727","DOI":"10.1016\/j.cmi.2017.08.028"},{"key":"12598","doi-asserted-by":"crossref","unstructured":"McCarthy MW, Keyloun KR, Gillard P, et al. Dalbavancin reduces hospital stay and improves productivity for patients with acute bacterial skin and skin structure infections: the ENHANCE trial. Infect Dis Ther. 2020;9(1):53-67. https:\/\/doi.org\/10.1007\/s40121-019-00275-4 PMID:31713130","DOI":"10.1007\/s40121-019-00275-4"},{"key":"12599","doi-asserted-by":"crossref","unstructured":"Rappo U, Gonzalez PL, Puttagunta S, et al. Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections. J Glob Antimicrob Resist. 2019;17:60-65. https:\/\/doi.org\/10.1016\/j.jgar.2019.02.007 PMID:30797084","DOI":"10.1016\/j.jgar.2019.02.007"}],"container-title":["Global and Regional Health Technology Assessment"],"original-title":[],"link":[{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/3094\/3665","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/3094\/3666","content-type":"application\/epub+zip","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/3094\/3667","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/3094\/3665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T11:07:25Z","timestamp":1722251245000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/view\/3094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":36,"journal-issue":{"issue":"Suppl. 2","published-online":{"date-parts":[[2024,7,29]]}},"URL":"https:\/\/doi.org\/10.33393\/grhta.2024.3094","relation":{},"ISSN":["2283-5733","2284-2403"],"issn-type":[{"value":"2283-5733","type":"electronic"},{"value":"2284-2403","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,29]]}}}